Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Void sorcerer: an open source, open access framework for mouse uroflowmetry.

Wang Z, Guzman EC, Nimunkar A, Keil KP, Vezina CM, Ricke WA, Macoska J, Bjorling DE.

Am J Clin Exp Urol. 2019 Jun 15;7(3):170-177. eCollection 2019.

2.

MRI-based method for lower urinary tract dysfunction in adult male mice.

McLean DT, Rutkowski DR, Liu T, Hernando D, Ricke WA, Roldán-Alzate A.

Am J Clin Exp Urol. 2019 Jun 15;7(3):153-158. eCollection 2019.

3.

Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the Medical Therapy of Prostatic Symptoms (MTOPS) Study.

Macoska JA, Uchtmann KS, Leverson GE, McVary KT, Ricke WA.

J Urol. 2019 Jun 12:101097JU0000000000000385. doi: 10.1097/JU.0000000000000385. [Epub ahead of print]

PMID:
31188728
4.

Expression and distribution of PIEZO1 in the mouse urinary tract.

Dalghi MG, Clayton DR, Ruiz WG, Al-Bataineh MM, Satlin LM, Kleyman TR, Ricke WA, Carattino MD, Apodaca G.

Am J Physiol Renal Physiol. 2019 Aug 1;317(2):F303-F321. doi: 10.1152/ajprenal.00214.2019. Epub 2019 Jun 5.

PMID:
31166705
5.

Prostate enlargement and altered urinary function are part of the aging process.

Liu TT, Thomas S, Mclean DT, Roldan-Alzate A, Hernando D, Ricke EA, Ricke WA.

Aging (Albany NY). 2019 May 13;11(9):2653-2669. doi: 10.18632/aging.101938.

6.

Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.

Sehgal PD, Bauman TM, Nicholson TM, Vellky JE, Ricke EA, Tang W, Xu W, Huang W, Ricke WA.

Hum Pathol. 2019 Jul;89:99-108. doi: 10.1016/j.humpath.2019.04.009. Epub 2019 May 3.

PMID:
31054895
7.

Quantitative proteomic analysis of a genetically induced prostate inflammation mouse model via custom 4-plex DiLeu isobaric labeling.

Hao L, Thomas S, Greer T, Vezina CM, Bajpai S, Ashok A, De Marzo AM, Bieberich CJ, Li L, Ricke WA.

Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1236-F1243. doi: 10.1152/ajprenal.00387.2018. Epub 2019 Apr 17.

PMID:
30995113
8.

Expression and Localization of DDX3 in Prostate Cancer Progression and Metastasis.

Vellky JE, Ricke EA, Huang W, Ricke WA.

Am J Pathol. 2019 Jun;189(6):1256-1267. doi: 10.1016/j.ajpath.2019.02.011. Epub 2019 Mar 27.

PMID:
30926334
9.

Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.

Hao L, Shi Y, Thomas S, Vezina CM, Bajpai S, Ashok A, Bieberich CJ, Ricke WA, Li L.

Int J Mass Spectrom. 2018 Nov;434:185-192. doi: 10.1016/j.ijms.2018.09.017. Epub 2018 Sep 22.

10.

Targeting a fibrotic bottleneck may provide an opening in the treatment of LUTS.

Ricke WA, Bruskewitz RC, Liu TT.

Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1091-F1093. doi: 10.1152/ajprenal.00102.2019. Epub 2019 Mar 13. No abstract available.

PMID:
30864837
11.

Inflammation, Voiding and Benign Prostatic Hyperplasia Progression.

Lloyd GL, Ricke WA, McVary KT.

J Urol. 2019 May;201(5):868-870. doi: 10.1097/JU.0000000000000049. No abstract available.

PMID:
30694937
12.

Modeling human prostate cancer progression in vitro.

Liu TT, Ewald JA, Ricke EA, Bell R, Collins C, Ricke WA.

Carcinogenesis. 2019 Jul 20;40(7):893-902. doi: 10.1093/carcin/bgy185.

PMID:
30590461
13.

Development of the human prostate.

Cunha GR, Vezina CM, Isaacson D, Ricke WA, Timms BG, Cao M, Franco O, Baskin LS.

Differentiation. 2018 Sep - Oct;103:24-45. doi: 10.1016/j.diff.2018.08.005. Epub 2018 Sep 4. Review.

PMID:
30224091
14.

Endocrine disruptor bisphenol A is implicated in urinary voiding dysfunction in male mice.

Nicholson TM, Nguyen JL, Leverson GE, Taylor JA, Vom Saal FS, Wood RW, Ricke WA.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1208-F1216. doi: 10.1152/ajprenal.00582.2017. Epub 2018 Jul 18.

PMID:
30019933
15.

Void spot assay procedural optimization and software for rapid and objective quantification of rodent voiding function, including overlapping urine spots.

Wegner KA, Abler LL, Oakes SR, Mehta GS, Ritter KE, Hill WG, Zwaans BM, Lamb LE, Wang Z, Bjorling DE, Ricke WA, Macoska J, Marker PC, Southard-Smith EM, Eliceiri KW, Vezina CM.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1067-F1080. doi: 10.1152/ajprenal.00245.2018. Epub 2018 Jul 4.

PMID:
29972322
16.

Prostate cancer xenografts and hormone induced prostate carcinogenesis.

McLean DT, Strand DW, Ricke WA.

Differentiation. 2017 Sep - Oct;97:23-32. doi: 10.1016/j.diff.2017.08.005. Epub 2017 Sep 8. Review.

17.

Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG.

Differentiation. 2017 Jul - Aug;96:49-61. doi: 10.1016/j.diff.2017.07.005. Epub 2017 Aug 4. Review.

18.

In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.

Hao L, Greer T, Page D, Shi Y, Vezina CM, Macoska JA, Marker PC, Bjorling DE, Bushman W, Ricke WA, Li L.

Sci Rep. 2016 Aug 9;6:30869. doi: 10.1038/srep30869.

19.

Comparison of Picrosirius Red Staining With Second Harmonic Generation Imaging for the Quantification of Clinically Relevant Collagen Fiber Features in Histopathology Samples.

Drifka CR, Loeffler AG, Mathewson K, Mehta G, Keikhosravi A, Liu Y, Lemancik S, Ricke WA, Weber SM, Kao WJ, Eliceiri KW.

J Histochem Cytochem. 2016 Sep;64(9):519-29. doi: 10.1369/0022155416659249. Epub 2016 Jul 22.

20.

Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial Cells.

Liu TT, Grubisha MJ, Frahm KA, Wendell SG, Liu J, Ricke WA, Auchus RJ, DeFranco DB.

J Biol Chem. 2016 Jul 8;291(28):14747-60. doi: 10.1074/jbc.M115.711515. Epub 2016 May 13.

21.

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging.

Bauman TM, Ricke EA, Drew SA, Huang W, Ricke WA.

J Vis Exp. 2016 Apr 8;(110). doi: 10.3791/53837.

22.

Monohaloacetic acid drinking water disinfection by-products inhibit follicle growth and steroidogenesis in mouse ovarian antral follicles in vitro.

Jeong CH, Gao L, Dettro T, Wagner ED, Ricke WA, Plewa MJ, Flaws JA.

Reprod Toxicol. 2016 Jul;62:71-6. doi: 10.1016/j.reprotox.2016.04.028. Epub 2016 May 2.

23.

Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progression.

Bauman TM, Vezina CM, Ricke EA, Halberg RB, Huang W, Peterson RE, Ricke WA.

Hum Pathol. 2016 May;51:124-33. doi: 10.1016/j.humpath.2015.12.024. Epub 2016 Jan 19.

24.

In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood.

Ricke WA, Lee CW, Clapper TR, Schneider AJ, Moore RW, Keil KP, Abler LL, Wynder JL, López Alvarado A, Beaubrun I, Vo J, Bauman TM, Ricke EA, Peterson RE, Vezina CM.

Toxicol Sci. 2016 Apr;150(2):429-40. doi: 10.1093/toxsci/kfw009. Epub 2016 Feb 9.

25.

Biomarker discovery in mass spectrometry-based urinary proteomics.

Thomas S, Hao L, Ricke WA, Li L.

Proteomics Clin Appl. 2016 Apr;10(4):358-70. doi: 10.1002/prca.201500102. Epub 2016 Feb 11. Review.

26.

SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.

Bauman TM, Becka AJ, Sehgal PD, Huang W, Ricke WA.

Hum Pathol. 2015 Nov;46(11):1744-51. doi: 10.1016/j.humpath.2015.07.015. Epub 2015 Jul 29.

27.

Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS).

Greer T, Hao L, Nechyporenko A, Lee S, Vezina CM, Ricke WA, Marker PC, Bjorling DE, Bushman W, Li L.

PLoS One. 2015 Aug 12;10(8):e0135415. doi: 10.1371/journal.pone.0135415. eCollection 2015.

28.

CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.

Bauman TM, Ewald JA, Huang W, Ricke WA.

BMC Cancer. 2015 Jul 25;15:549. doi: 10.1186/s12885-015-1559-4.

29.

Estrogens and Male Lower Urinary Tract Dysfunction.

Wynder JL, Nicholson TM, DeFranco DB, Ricke WA.

Curr Urol Rep. 2015 Sep;16(9):61. doi: 10.1007/s11934-015-0534-6. Review.

30.

Evaluation of voiding assays in mice: impact of genetic strains and sex.

Bjorling DE, Wang Z, Vezina CM, Ricke WA, Keil KP, Yu W, Guo L, Zeidel ML, Hill WG.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1369-78. doi: 10.1152/ajprenal.00072.2015. Epub 2015 Apr 22.

31.

Impact of a folic acid-enriched diet on urinary tract function in mice treated with testosterone and estradiol.

Keil KP, Abler LL, Altmann HM, Wang Z, Wang P, Ricke WA, Bjorling DE, Vezina CM.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1431-43. doi: 10.1152/ajprenal.00674.2014. Epub 2015 Apr 8.

32.

Microfluidic multiculture assay to analyze biomolecular signaling in angiogenesis.

Theberge AB, Yu J, Young EW, Ricke WA, Bushman W, Beebe DJ.

Anal Chem. 2015 Mar 17;87(6):3239-46. doi: 10.1021/ac503700f. Epub 2015 Feb 26.

33.

Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue.

Bauman TM, Vezina CM, Huang W, Marker PC, Peterson RE, Ricke WA.

Am J Clin Exp Urol. 2014 Dec 25;2(4):313-22. eCollection 2014.

34.

The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.

Moses MA, Henry EC, Ricke WA, Gasiewicz TA.

Cancer Prev Res (Phila). 2015 Mar;8(3):249-57. doi: 10.1158/1940-6207.CAPR-14-0224. Epub 2015 Jan 20.

35.

Influence of animal husbandry practices on void spot assay outcomes in C57BL/6J male mice.

Keil KP, Abler LL, Altmann HM, Bushman W, Marker PC, Li L, Ricke WA, Bjorling DE, Vezina CM.

Neurourol Urodyn. 2016 Feb;35(2):192-8. doi: 10.1002/nau.22692. Epub 2014 Nov 12.

36.

Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules.

Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, Ricke WA.

PLoS One. 2014 Oct 2;9(10):e109102. doi: 10.1371/journal.pone.0109102. eCollection 2014.

37.

Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.

Nicholson TM, Moses MA, Uchtmann KS, Keil KP, Bjorling DE, Vezina CM, Wood RW, Ricke WA.

J Urol. 2015 Feb;193(2):722-9. doi: 10.1016/j.juro.2014.08.093. Epub 2014 Aug 25.

38.

Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013.

Peretz J, Vrooman L, Ricke WA, Hunt PA, Ehrlich S, Hauser R, Padmanabhan V, Taylor HS, Swan SH, VandeVoort CA, Flaws JA.

Environ Health Perspect. 2014 Aug;122(8):775-86. doi: 10.1289/ehp.1307728. Epub 2014 Jun 4. Review.

39.

Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.

Bauman TM, Sehgal PD, Johnson KA, Pier T, Bruskewitz RC, Ricke WA, Huang W.

Prostate. 2014 Jun;74(9):923-32. doi: 10.1002/pros.22810. Epub 2014 Apr 30.

40.

Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.

Lewis SR, Hedman CJ, Ziegler T, Ricke WA, Jorgensen JS.

Endocrinology. 2014 Feb;155(2):358-69. doi: 10.1210/en.2013-1583. Epub 2013 Nov 21.

41.

Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia.

Nicholson TM, Uchtmann KS, Valdez CD, Theberge AB, Miralem T, Ricke WA.

J Vis Exp. 2013 Aug 28;(78). doi: 10.3791/50574.

42.

Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Nicholson TM, Sehgal PD, Drew SA, Huang W, Ricke WA.

Differentiation. 2013 Apr-Jun;85(4-5):140-9. doi: 10.1016/j.diff.2013.02.006. Epub 2013 Jun 20.

43.

Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.

Ewald JA, Downs TM, Cetnar JP, Ricke WA.

PLoS One. 2013;8(2):e55414. doi: 10.1371/journal.pone.0055414. Epub 2013 Feb 1.

44.

Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice.

Nicholson TM, Ricke EA, Marker PC, Miano JM, Mayer RD, Timms BG, vom Saal FS, Wood RW, Ricke WA.

Endocrinology. 2012 Nov;153(11):5556-65. doi: 10.1210/en.2012-1522. Epub 2012 Sep 4.

45.

An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer.

Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M.

J Mens Health. 2012 Sep 1;9(3):182-189.

46.

Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.

Ricke EA, Williams K, Lee YF, Couto S, Wang Y, Hayward SW, Cunha GR, Ricke WA.

Carcinogenesis. 2012 Jul;33(7):1391-8. doi: 10.1093/carcin/bgs153. Epub 2012 Apr 25.

47.

LC/LC-MS/MS of an innovative prostate human epithelial cancer (PHEC) in vitro model system.

Lapek JD Jr, McGrath JL, Ricke WA, Friedman AE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 15;893-894:34-42. doi: 10.1016/j.jchromb.2012.02.029. Epub 2012 Mar 3.

48.

Developmental, cellular and molecular biology of benign prostatic hyperplasia.

Ricke WA, Macoska JA, Cunha GR.

Differentiation. 2011 Nov-Dec;82(4-5):165-7. doi: 10.1016/j.diff.2011.08.005. Epub 2011 Aug 30. No abstract available.

49.

A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia.

Cunha GR, Ricke WA.

Differentiation. 2011 Nov-Dec;82(4-5):168-72. doi: 10.1016/j.diff.2011.04.002. Epub 2011 Jun 30. Review.

50.

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Nicholson TM, Ricke WA.

Differentiation. 2011 Nov-Dec;82(4-5):184-99. doi: 10.1016/j.diff.2011.04.006. Epub 2011 May 26. Review.

Supplemental Content

Loading ...
Support Center